October 2019 Issue Table Of Contents

From The Editor

• It’s About Time The Business Roundtable Got With The Times

Feature Articles

• Building A $1 Billion Gene Therapy Company — In 6 Years
• Impact Investing — The Next BIG Thing In Life Sciences?

Capitol Perspectives

• Hospitals Drive More Costs, Get Less Scrutiny

CEO Corner

• From Consumer Products CEO To Biopharma CEO

From Principles and Policy to Execution

• Renewed Focus On Prevention Is Necessary To Improve Population Well Being

Companies To Watch

• eXIthera

Industry Research

• mHealth Implementation — Use By Therapeutic Area

Inside The Industry

• Potential Solutions To Current Pricing Models For Cell And Gene Therapies
• Regulators Emphasize Patience In Tailored Biosimilar Development
• Areas Of Growth For Oral-Dose Outsourcing
• Program Winners Look Back On Year Of Change
• Taking A Strengths-Based Approach To Diversity & Inclusion

Leadership Lessons

• Corporate Leaders Stifle Employees

Ask The Board

• What Is The Most Ridiculous Justification You Have Ever Heard To Rationalize An Inefficient /Expensive Capital Structure?
• What Was The Most Valuable Experience/Training That Prepared You For The Role Of CFO?
• What Advice Do You Have For Women Interested In Becoming Senior-Level Leaders And Serving On Corporate Boards Of Biopharma Companies?